Drug maker Lupine on Tuesday stated it has launched Sevelamer Hydrochloride tablets (800 mg), used to deal with hyperphosphatemia in sufferers with power kidney illness, within the US market.
The corporate has launched the product after having acquired approval from the US Meals and Drug Administration (USFDA).
The remedy will likely be manufactured on the firm’s manufacturing facility in Nagpur, Lupine stated in an announcement.
Hyperphosphatemia refers to abnormally excessive serum phosphate ranges.
The corporate’s product is a generic equal of Genzyme Company’s Renagel tablets.
As per IQVIA MAT December 2021 information, Sevelamer Hydrochloride tablets (800 mg) had an estimated annual gross sales of USD 75 million within the US.
(Solely the headline and movie of this report could have been reworked by the Enterprise Normal workers; the remainder of the content material is auto-generated from a syndicated feed.)
Enterprise Normal has at all times strived arduous to supply up-to-date info and commentary on developments which are of curiosity to you and have wider political and financial implications for the nation and the world. Your encouragement and fixed suggestions on enhance our providing have solely made our resolve and dedication to those beliefs stronger. Even throughout these tough occasions arising out of Covid-19, we proceed to stay dedicated to conserving you knowledgeable and up to date with credible information, authoritative views and incisive commentary on topical problems with relevance. We, nevertheless, have a request.
As we battle the financial influence of the pandemic, we’d like your assist much more, in order that we will proceed to give you extra high quality content material. Our subscription mannequin has seen an encouraging response from a lot of you, who’ve subscribed to our on-line content material. Extra subscription to our on-line content material can solely assist us obtain the targets of providing you even higher and extra related content material. We imagine in free, truthful and credible journalism. Your assist by extra subscriptions may help us apply the journalism to which we’re dedicated.
Help high quality journalism and subscribe to Enterprise Normal,